ESMO 2024 | TOMBOLA: advancements in post-operative treatment strategies in bladder cancer

Jorgen Bjerggaard Jensen • 15 Sep 2024

ESMO 2024

TOMBOLA

Jorgen Bjerggaard Jensen, MD, Aarhus University Hospital, Aarhus, Denmark, comments on the impact of the TOMBOLA trial (NCT04138628), which assessed the use of circulating tumor DNA (ctDNA) to guide post-operative treatment in patients with high-risk bladder cancer. One-third of these patients might be able to skip adjuvant therapy, thereby emphasizing the possibility of personalized treatment strategies. He also emphasizes the shift towards considering treatment during biochemical recurrence rather than traditional adjuvant therapy, particularly as low-risk patients still face recurrence. interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.